Status:
WITHDRAWN
Stem Cells in NF1 Patients With Tumors of the Central Nervous System
Lead Sponsor:
Roger Packer
Conditions:
Neurofibromatosis Type 1
Tumors of the Central Nervous System
Eligibility:
All Genders
Brief Summary
Objectives 1. Establish an induced pluripotent stem cell (iPSC) bank for phenotypically well-characterized patients with NF1. 2\. Develop isogenic NF1 wild-type (NF1+/+), NF1 heterozygous (NF1+/-) an...
Detailed Description
Hypothesis: Subjects with NF1 and central nervous system tumors who have aggressive lesions (including, but not limited to optic pathway gliomas) and/or those with tumors causing neurologic (including...
Eligibility Criteria
Inclusion
- Males or females of any age
- Confirmed diagnosis of NF1
- Willingness to submit blood sample and collect clinical history
- MRI documentation confirming tumor location in the central nervous system.
- For study group d, "Non-NF1 full sibling for control purposes" subject must be a full sibling of a patient with confirmed diagnosis of NF1 and willing to submit blood sample and collect clinical history.
Exclusion
- Does not have diagnosis of NF1 and CNS Tumor
- Does not have full-sibling with NF1 and CNS Tumor diagnosis (for unaffected sibling cohort)
Key Trial Info
Start Date :
November 27 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 1 2025
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT03332030
Start Date
November 27 2015
End Date
July 1 2025
Last Update
February 7 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Children's National Medical Center
Washington D.C., District of Columbia, United States, 20010